U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H34FN7O4
Molecular Weight 479.5483
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LANOPEPDEN

SMILES

[H][C@]12COCCN1CCN(C2)C3=C(F)C(NNC(=O)[C@H](CC4CCCC4)CN(O)C=O)=NC(C)=N3

InChI

InChIKey=SWHNZGMQMGFQGW-MSOLQXFVSA-N
InChI=1S/C22H34FN7O4/c1-15-24-20(19(23)21(25-15)29-7-6-28-8-9-34-13-18(28)12-29)26-27-22(32)17(11-30(33)14-31)10-16-4-2-3-5-16/h14,16-18,33H,2-13H2,1H3,(H,27,32)(H,24,25,26)/t17-,18+/m1/s1

HIDE SMILES / InChI

Molecular Formula C22H34FN7O4
Molecular Weight 479.5483
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

LANOPEPDEN is an inhibitor of peptide deformylase, a bacterial enzyme required for protein maturation. It was in development for the treatment of complicated bacterial skin infection and hospitalized community-acquired pneumonia.

Approval Year

PubMed

PubMed

TitleDatePubMed
Antibiotics in development targeting protein synthesis.
2011 Dec
Determination of disk diffusion and MIC quality control ranges for GSK1322322, a novel peptide deformylase inhibitor.
2011 Nov
Patents

Sample Use Guides

Lanopepden (GSK1322322) had an MIC90 of 1 μg/ml against M. catarrhalis and 4 μg/ml against H. influenzae, with 88.8% of beta-lactamase-positive strains showing growth inhibition at that concentration. All S. pneumoniae strains were inhibited by ≤ 4 μg/ml of GSK1322322, with an MIC90 of 2 μg/ml. GSK1322322 was very potent against S. pyogenes strains, with an MIC90 of 0.5 μg/ml, irrespective of their macrolide resistance phenotype. It was also active against S. aureus strains regardless of their susceptibility to methicillin, macrolides, or levofloxacin, with an MIC90 of 4 μg/ml in all cases.
Substance Class Chemical
Created
by admin
on Sat Dec 16 03:01:36 GMT 2023
Edited
by admin
on Sat Dec 16 03:01:36 GMT 2023
Record UNII
12M6KFD07E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LANOPEPDEN
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
lanopepden [INN]
Common Name English
CYCLOPENTANEPROPANOIC ACID, .ALPHA.-((FORMYLHYDROXYAMINO)METHYL)-, 2-(5-FLUORO-6-((9AS)-HEXAHYDROPYRAZINO(2,1-C)(1,4)OXAZIN-8(1H)-YL)-2-METHYL-4-PYRIMIDINYL)HYDRAZIDE, (.ALPHA.R)-
Common Name English
Lanopepden [WHO-DD]
Common Name English
GSK-1322322B
Code English
GSK-322
Code English
LANOPEPDEN [USAN]
Common Name English
GSK1322322
Code English
GSK-1322322
Code English
GSK1322322B
Code English
Code System Code Type Description
USAN
BC-70
Created by admin on Sat Dec 16 03:01:36 GMT 2023 , Edited by admin on Sat Dec 16 03:01:36 GMT 2023
PRIMARY
DRUG BANK
DB11912
Created by admin on Sat Dec 16 03:01:36 GMT 2023 , Edited by admin on Sat Dec 16 03:01:36 GMT 2023
PRIMARY
NCI_THESAURUS
C166453
Created by admin on Sat Dec 16 03:01:36 GMT 2023 , Edited by admin on Sat Dec 16 03:01:36 GMT 2023
PRIMARY
PUBCHEM
52918384
Created by admin on Sat Dec 16 03:01:36 GMT 2023 , Edited by admin on Sat Dec 16 03:01:36 GMT 2023
PRIMARY
CAS
1152107-25-9
Created by admin on Sat Dec 16 03:01:36 GMT 2023 , Edited by admin on Sat Dec 16 03:01:36 GMT 2023
PRIMARY
EPA CompTox
DTXSID00151006
Created by admin on Sat Dec 16 03:01:36 GMT 2023 , Edited by admin on Sat Dec 16 03:01:36 GMT 2023
PRIMARY
FDA UNII
12M6KFD07E
Created by admin on Sat Dec 16 03:01:36 GMT 2023 , Edited by admin on Sat Dec 16 03:01:36 GMT 2023
PRIMARY
ChEMBL
CHEMBL3301608
Created by admin on Sat Dec 16 03:01:36 GMT 2023 , Edited by admin on Sat Dec 16 03:01:36 GMT 2023
PRIMARY
INN
10045
Created by admin on Sat Dec 16 03:01:36 GMT 2023 , Edited by admin on Sat Dec 16 03:01:36 GMT 2023
PRIMARY
SMS_ID
300000034284
Created by admin on Sat Dec 16 03:01:36 GMT 2023 , Edited by admin on Sat Dec 16 03:01:36 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
EXCRETED UNCHANGED
ORAL ADMINISTRATION
URINE
EXCRETED UNCHANGED
INTRAVENOUS ADMINISTRATION
URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

Biological Half-life PHARMACOKINETIC INTRAVENOUS ADMINISTRATION